List of Excipients in Branded Drug VISIPAQUE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
GE Healthcare Inc	VISIPAQUE	iodixanol	0407-2222	CALCIUM CHLORIDE
GE Healthcare Inc	VISIPAQUE	iodixanol	0407-2222	EDETATE CALCIUM DISODIUM
GE Healthcare Inc	VISIPAQUE	iodixanol	0407-2222	HYDROCHLORIC ACID
GE Healthcare Inc	VISIPAQUE	iodixanol	0407-2222	SODIUM CHLORIDE
GE Healthcare Inc	VISIPAQUE	iodixanol	0407-2222	SODIUM HYDROXIDE
GE Healthcare Inc	VISIPAQUE	iodixanol	0407-2222	TROMETHAMINE

VISIPAQUE Excipient Strategy and Commercial Opportunities

Last updated: August 7, 2026

Visipaque, the iodixanol-based low-osmolar contrast agent, has limited opportunity for premium excipient innovation because its core formulation is mature and generic competition is established. The strongest commercial opportunities are in supply security, container systems, ready-to-use presentation, dose optimization, cold-chain resilience, and manufacturing cost reduction.

Visipaque is marketed in 270 mg iodine/mL and 320 mg iodine/mL strengths for intravascular administration. Its excipient system is intentionally restrained and supports three primary objectives: pH control, metal-ion control, and isotonicity management. The product is a small-molecule contrast medium, so biosimilar risk does not apply. Generic iodixanol products, procurement competition, and hospital conversion risk are the central commercial threats.

What excipients are used in Visipaque?

Visipaque contains iodixanol as the active pharmaceutical ingredient and a small excipient system centered on tromethamine, calcium disodium edetate, sodium chloride, and water for injection. The exact quantitative composition varies by product presentation and should be controlled against the current FDA-approved labeling.

Component	Functional role	Commercial relevance
Iodixanol	Nonionic dimeric contrast agent	Determines iodine concentration, viscosity, osmolality, and clinical positioning
Tromethamine	Buffer and pH-control agent	Supports formulation stability and injectable compatibility
Calcium disodium edetate	Chelating agent	Controls trace-metal catalyzed degradation and supports impurity management
Sodium chloride	Tonicity adjustment	Helps align the finished formulation with injection requirements
Water for injection	Vehicle	Controls microbial, endotoxin, and extractables risk

The FDA label identifies Visipaque as a nonionic, water-soluble, dimeric contrast medium. The formulation is supplied as a sterile injectable solution and is not dependent on a preservative system for multidose antimicrobial protection.[1]

Why does Visipaque use a minimal excipient system?

The excipient strategy reduces interaction risk with a highly concentrated iodinated molecule. Adding surfactants, cosolvents, antioxidants, or antimicrobial preservatives could create new concerns involving injection-site tolerability, extractables, particulate formation, compatibility with automated injectors, or regulatory comparability.

Tromethamine provides buffering without introducing a complex multicomponent buffer system. Calcium disodium edetate provides trace-metal control at low concentration. Sodium chloride adjusts tonicity without materially changing the chemical environment of the solution.

This architecture is commercially important because generic manufacturers can reproduce the formulation with relatively limited excipient differentiation. A competing product is more likely to win through price, supply reliability, packaging, or hospital contracting than through a visibly different excipient profile.

What formulation attributes make Visipaque difficult to reformulate?

High iodine concentration and viscosity

The 320 mg iodine/mL presentation has higher viscosity than the 270 mg iodine/mL presentation. Any excipient change must preserve injectability through power injectors and maintain acceptable administration characteristics across temperature conditions.

A formulation that reduces viscosity could have commercial value, particularly for computed tomography and angiographic workflows. The opportunity is technically difficult because viscosity is strongly influenced by iodixanol concentration, temperature, molecular structure, and total dissolved solids.

Osmolality and renal tolerability

Visipaque is classified as an iso-osmolar contrast medium relative to plasma at clinically relevant concentrations. That characteristic supports its positioning in patients for whom osmotic load is a consideration.[1]

An excipient change that raises osmolality could weaken the product's clinical differentiation. The principal formulation objective is therefore not simply lower cost. It is preservation of osmolality, iodine delivery, pH, sterility, and injectability after any change.

Trace-metal control

The chelating agent is a small but important part of the stability strategy. Removing or reducing calcium disodium edetate could lower material cost, but it could also increase the risk of trace-metal-mediated color change, degradation, or shelf-life failure.

The commercial opportunity is to improve control of trace metals in raw materials, process water, and manufacturing equipment. A manufacturer that achieves equivalent stability with tighter incoming-material specifications may obtain a cost advantage without changing the labeled excipient composition.

What excipient patents protect Visipaque?

The original patent estate around iodixanol, its preparation, and its use is mature. The most important commercial protection for Visipaque historically came from patents covering the active contrast agent and related manufacturing technology rather than from a distinctive excipient combination.

The key distinction is between:

1. Patents covering iodixanol or its chemical production.
2. Patents covering a specific iodixanol injectable composition.
3. Patents covering packaging, administration devices, or injector compatibility.
4. Patents covering clinical methods of using iodixanol.
5. Trade secrets covering impurity control, crystallization, purification, and scale-up.

Excipient modifications can create new patent opportunities, but a simple substitution of tromethamine, edetate, sodium chloride, or water for injection is unlikely to produce a strong composition-of-matter position by itself. A stronger patent strategy would require a demonstrated technical effect, such as:

• lower viscosity at equivalent iodine concentration;
• improved stability under elevated-temperature storage;
• reduced particulate formation;
• compatibility with a specific automated injector;
• reduced container interaction;
• improved delivery through small-bore catheters;
• lower waste through a ready-to-use presentation;
• improved stability after partial use in a controlled clinical workflow.

FDA Orange Book status, current patent listings, and any certifications for generic iodixanol applications must be checked against the current edition and applicable FDA records. The commercial market should be analyzed as a genericized small-molecule market rather than a biologic exclusivity market.[2]

When did Visipaque lose exclusivity?

Visipaque's primary market protection is no longer dependent on active new-drug exclusivity. The product was approved in the United States in the 1990s, and the relevant commercial issue is generic entry and contracting rather than loss of a near-term regulatory exclusivity period.[1]

A generic iodixanol applicant can pursue an abbreviated new drug application if it meets the applicable requirements for pharmaceutical equivalence, bioequivalence or comparable performance, sterility, labeling, and manufacturing quality. Contrast agents also face practical review issues involving concentration, viscosity, osmolality, container closure, and injector use.

The primary entry scenarios are:

Entry scenario	Likely commercial effect
Single generic supplier	Moderate price pressure, limited immediate conversion
Multiple approved suppliers	Material price erosion and stronger hospital tender competition
Authorized or contract-manufactured supply	Greater continuity but lower brand differentiation
Formulation or device-enhanced competitor	Potential premium niche in imaging centers and high-throughput hospitals

What generic entry risks exist for Visipaque?

Generic entry risk is high at the molecule level because iodixanol is a well-characterized small molecule with long clinical use. The principal barriers are manufacturing complexity, sterile injectable quality, supply scale, and hospital procurement qualification.

Paragraph IV challenges

Paragraph IV litigation is relevant if an applicant certifies that listed patents are invalid, unenforceable, or not infringed. For a mature contrast agent, the most likely dispute targets are residual formulation, manufacturing, use, or packaging patents rather than the basic active ingredient.

The strategic value of a Paragraph IV case depends on whether the challenged patent can support a 30-month stay, whether the listed patent is commercially meaningful, and whether the generic can launch at risk. Patent certifications should be assessed against the current Orange Book listing for the applicable iodixanol reference product.[2]

Manufacturing barriers

Iodixanol production requires control of highly concentrated solutions, impurities, residual solvents, stereochemical composition, and batch-to-batch iodine concentration. A generic manufacturer may have legal freedom to enter but still face elevated cost and yield risk.

The most durable non-patent barriers are:

• reliable iodixanol API supply;
• sterile fill-finish capacity;
• control of visible and subvisible particles;
• validated container closure systems;
• compatibility with power injectors;
• global regulatory consistency;
• inventory management for multiple vial and bottle sizes.

What formulation patents could create commercial value?

A new formulation patent should be built around measurable performance rather than excipient substitution alone.

Lower-viscosity iodixanol formulations

Lower-viscosity products could reduce injection pressure and improve workflow in CT angiography. The strongest claims would tie a specific excipient ratio or concentration range to a verified viscosity reduction while preserving iodine concentration and osmolality.

Temperature-stable presentations

Contrast media are commonly handled across hospital storage, transport, and imaging environments. A formulation or package that reduces temperature-related viscosity changes could support faster preparation and fewer warming steps.

Injector-compatible packaging

A container designed for automated contrast injectors may provide more practical value than a new excipient. Relevant claim areas include septum performance, connection geometry, pressure tolerance, residual volume, and reduced transfer steps.

Reduced-waste products

Single-use syringes, prefilled cartridges, and smaller dose presentations can reduce waste in outpatient imaging. The commercial value is strongest where the product minimizes unused contrast after a patient-specific procedure.

Container-closure systems

Glass, polymer, elastomer, and overwrap choices can affect extractables, leachables, breakage, handling, and shipping cost. A package patent could protect a commercially useful combination even if the formulation remains chemically unchanged.

What FDA regulatory status applies to Visipaque?

Visipaque is an FDA-approved prescription injectable contrast medium. It is used for intra-arterial and intravenous procedures, including computed tomography, angiography, digital subtraction angiography, and other radiographic imaging applications identified in the prescribing information.[1]

Because it is a sterile injectable, formulation changes can trigger substantial regulatory work. A change to an inactive ingredient may require updated stability, compatibility, particulate, sterility, endotoxin, extractables, leachables, and container-closure data. The regulatory pathway depends on whether the change is made to the reference product, a generic product, or a new drug-device combination.

The FDA labeling also contains warnings related to hypersensitivity reactions, acute kidney injury risk, thyroid dysfunction, extravasation, and other contrast-associated events. Excipient strategy cannot be separated from the product's clinical risk profile.[1]

How does Visipaque compare with competing contrast agents?

Product	Active ingredient	Osmolality positioning	Principal competitive issue
Visipaque	Iodixanol	Iso-osmolar	Higher formulation and manufacturing cost
Omnipaque	Iohexol	Low-osmolar	Broad use, strong hospital familiarity
Isovue	Iopamidol	Low-osmolar	Established angiography and CT presence
Ultravist	Iopromide	Low-osmolar	Global imaging and hospital competition
Optiray	Ioversol	Low-osmolar	Price and supply competition

Visipaque's principal differentiator is its iso-osmolar profile. Competitors can offset that advantage with lower acquisition cost, established protocols, broad presentations, and contracting strength.

Excipient differentiation is unlikely to displace these products unless it produces a clear operational benefit. A hospital buyer is more likely to value injector compatibility, reliable supply, lower waste, and total procedure cost than a change in buffer or chelator.

What licensing and commercial opportunities exist for Visipaque excipients?

The most credible licensing opportunities are platform-based rather than Visipaque-specific.

Excipient and formulation platforms

A company with a low-viscosity, low-osmolality, or high-concentration injectable platform could license technology for use with iodixanol and other contrast agents. The license should cover composition, manufacturing process, and analytical methods.

Container and injector partnerships

Device manufacturers can pursue co-development with contrast suppliers for prefilled syringes, cartridges, and automated injector systems. Revenue may come from device sales, consumables, supply agreements, or bundled imaging contracts.

Contract manufacturing

Sterile fill-finish providers can compete for generic iodixanol production, particularly where they have established capacity for high-volume injectable products. Supply continuity and dual sourcing are valuable in hospital tenders.

Regional commercialization

Emerging markets may offer opportunities for local licensing, secondary packaging, and regional fill-finish. The principal requirements are regulatory registration, pharmacovigilance, cold-chain or controlled-room-temperature logistics, and procurement access.

How strong is the Visipaque patent estate?

The patent estate is strong historically at the active-ingredient and manufacturing-technology level but weaker as a basis for new branded exclusivity. The original molecule and long-established formulation are mature. Future protection is more likely to arise from specific improvements than from the core Visipaque formulation.

A commercial diligence review should rank assets by:

1. Remaining patent term.
2. Claim scope around iodixanol, excipients, process steps, or packaging.
3. Enforceability in the United States, Europe, China, Japan, and major tender markets.
4. Freedom-to-operate against generic iodixanol.
5. Evidence of clinical or manufacturing benefit.
6. Ability to support regulatory differentiation.

Key Takeaways

• Visipaque uses a compact excipient system built around tromethamine, calcium disodium edetate, sodium chloride, and water for injection.
• The main formulation constraints are viscosity, osmolality, pH, trace-metal control, sterility, and injector compatibility.
• The product is a mature small-molecule contrast agent with generic entry risk, not a biosimilar market.
• Excipient substitution alone is unlikely to support durable premium pricing or strong patent protection.
• The best commercial opportunities are lower-viscosity formulations, injector-compatible packaging, reduced-waste presentations, temperature-stable products, and manufacturing-cost improvements.
• Manufacturing scale, sterile fill-finish capability, supply reliability, and hospital contracting are more important competitive factors than minor excipient changes.
• Any current patent or Paragraph IV analysis must use the latest FDA Orange Book and applicable litigation records.

FAQs

Can a generic manufacturer change Visipaque excipients?

Yes, subject to applicable FDA requirements. The applicant must demonstrate that the formulation remains pharmaceutically equivalent or otherwise meets the relevant regulatory standard and does not introduce material safety, stability, or performance differences.

Is calcium disodium edetate essential to iodixanol stability?

It is part of the labeled formulation and functions as a chelating agent. Its removal or reduction would require evidence that trace-metal control and product stability remain acceptable.

Could a preservative improve Visipaque commercial value?

Usually not for the existing single-use injectable model. A preservative could create compatibility, tolerability, regulatory, and labeling issues. The stronger opportunity is often improved single-use packaging or dose presentation.

Are prefilled iodixanol syringes patentable?

Potentially. Patentability would depend on the specific syringe, connector, closure, injector interface, residual-volume control, or formulation performance, not merely placing iodixanol in a prefilled container.

Does Visipaque have biosimilar competition?

No. Iodixanol is a chemically defined small molecule. Competitive entry occurs through generic drug pathways and branded contrast-agent substitution, not biosimilar approval.

References

1. U.S. Food and Drug Administration. (2024). Visipaque (iodixanol injection) prescribing information. GE Healthcare.

2. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.